- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04919876
Phytochemicals on "Metabolic Aging" in Older Overweight Adults
The Impact of a Phytochemical Supplement on "Metabolic Aging" in Older Overweight Adults Relative to Young Lean Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Advanced age is associated with reduced mitochondrial capacity and altered metabolomic signatures relative to those at younger ages. We hypothesize that supplemental fruit and vegetable phytochemicals will slow or reverse signs of metabolic aging by enhancing mitochondrial capacity in older, overweight/obese adults as well as shift their metabolomic signature toward those of younger, leaner adults. To test this hypothesis, we will pursue the following specific aims in a controlled feeding trial to diminish the confounding effect of concurrent and confounding dietary factors.
Specific Aim 1: To determine the extent to which supplemental fruit and vegetable concentrates will shift the mitochondrial capacity of peripheral blood mononuclear cells in older, overweight older adults toward that of young, lean adults.
Specific Aim 2: To determine the extent to which supplemental fruit and vegetable concentrates will shift the plasma metabolomic signature of older, overweight adults toward that of young, lean adults.
The experimental design is a randomized, double-blind, placebo-controlled, parallel design, controlled feeding trial. This trial will enroll 40 older adults, as well as 20 younger adults to serve as a reference, to complete the study. They will be generally healthy. The older adults will be ≥55 y and have BMI >27.0 and <35 kg/m2, and the younger adults will be 18-30 y and have BMI >18.5 and <27 kg/m2. The older subjects will be randomized to receive either placebo (PLA) or fruit/vegetable supplement (FVS) for 6 weeks after a 2-wk run-in period. The younger adults serving as the reference group for the older subjects will only participate in the run-in period and will not receive any dietary supplements. During the whole study, including the run-in period, all subjects will consume provided meals. The total duration of the trial will be ~10 weeks for the older subjects, including screening, 2-wk run-in, and 6 wk of intervention, as well as ~4 weeks for the younger subjects including screening and 2-wk run-in. In addition to consuming the provided meals for 6 weeks, the older volunteers will take an assigned supplement daily. Blood samples of the older volunteers will be collected at the end of the run-in and the end of the 6-wk intervention. These same samples will only be collected from the younger volunteers at the end of the run-in period.
Older subjects will be randomly assigned to receive one of the supplements (PLA vs. FVS) after their eligibility is confirmed. A randomization scheme will be prepared by a biostatistician using a standardized computer program for two treatment groups using a parallel design.
The study supplements will be generously provided by Juice PLUS (Collierville, TN). A matching placebo product will be manufactured by the Juice PLUS under the FDA GMP guidelines. The main ingredient of the placebo will be microcrystalline cellulose-containing 0.5% magnesium stearate. The Juice PLUS products that will be used in this intervention have been marketed in the US. Microcrystalline cellulose and magnesium stearate have a GRAS status under FDA Code of Federal Regulations (CFR) title 21. FVS in a capsule form will be the combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend. All Juice Plus+ supplements contain a fine, granular powder, mainly from botanical ingredients. This powder is encapsulated in a size 00 gelatin capsule. These three formulas will be blended to produce a uniform brown powder and packaged into study opaque capsules.
Juice Plus+ Garden Blend consists of vegetable juice powder and pulp from carrot, parsley, beet, kale, broccoli, cabbage, spinach, oat, rice, and tomato; gelatin, glucomannan, calcium ascorbate, mixed tocopherols, calcium carbonate, garlic powder, Spirulina Pacifica, natural mixed carotenoids, natural enzyme blend, Lactobacillus acidophilus, folic acid. The powder looks pale green in color and smells like cabbage. Juice Plus+ Orchard Blend consists of fruit juice powder and pulp from apple, orange, pineapple, cranberry, peach, acerola cherry, beet, prune, date, and papaya; gelatin, calcium ascorbate, citrus pectin, citrus bioflavonoids, glucomannan, natural mixed carotenoids, natural enzyme blend, bromelain, papain, mixed tocopherols, Lactobacillus acidophilus, folic acid. The powder looks pink in color and smells like apple/cranberry. Juice Plus+ Berry Blend consists of fruit juice and pulp powder of Concord grape, blueberry, cranberry, blackberry, bilberry, raspberry, black currant, elderberry, cocoa powder, pomegranate powder, green tea, ginger root, grape seed, and artichoke leaf powder, gelatin, mixed tocopherols, calcium ascorbate, natural enzyme blend, silicon dioxide, vegetable-derived magnesium stearate, citrus bioflavonoids from tangerine, folic acid. The powder looks purple in color and smells faintly of berry and cocoa.
During the trial, older subjects will be required to attend 1 screening visit and 3 study visits over 10 weeks, and younger subjects will be required to attend 1 screening visit and 2 study visits over 4 weeks. An initial screening visit (Visit 1) is employed to obtain informed consent and determine each subject's eligibility. A blood sample will be collected only if the subject is fasting >12 hours. At Visit 2, subjects will begin to consume the provided meals for 2 weeks during the run-in period. At Visit 3, all subjects will be asked to arrive at the study site after fasting for >12 h, blood will be collected. For younger subjects, the study will complete at end of Visit 3. Older subjects will be randomly assigned to one of 2 supplements, starting on the next day of Visit 3 for 6 weeks. They will be instructed to take 3 capsules each with breakfast and dinner. At Visit 4 (final visit), older subjects will be asked to arrive at the study site after fasting for >12 h, blood will be collected for analyses.
Younger and older subjects will consume provided meals for 2 and 8 weeks. The study meals will be designed to be comparable to a diet that most average Americans are consuming. Subjects may consume the study meals longer than 2 or 8 weeks because of a visit scheduling conflict or other unexpected events.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Oliver Chen, PhD
- Phone Number: 6175563128
- Email: oliver.chen@tufts.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Recruiting
- Jean Mayer USDA Human Nutrition Research Center on Aging
-
Contact:
- Chery H Gilhooly, PhD
- Phone Number: 617-556-3154
- Email: Cheryl.Gilhooly@tufts.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Generally healthy
- Age, ≥55 y old
- BMI, ≥27 and <35 kg/m2
- Consume a typical American diet, <3 servings of combined fruits and vegetables daily
- Waist:hip ratio >0.8 for women and >0.9 for men, and waist:height ratio ≥0.5
- Willing to consume study meals for 8 wk
- Do not have allergic reaction to plant foods
- Willing to take the assigned supplement for 6 wk
Exclusion Criteria:
- Unusual dietary pattern, including vegan/vegetarian
- Cigarette smoking and/or nicotine replacement use in the last 6 months
- Intend to be pregnant, pregnancy, and breastfeeding
- Use of medications known to change lipid metabolism
- Steroid use, except nasal and non-prescription topical treatments
- Active treatment for cancer of any type >1 y, except non-melanoma skin cancer
- Have an immunodeficiency condition
- Use of immunosuppressive medications within the last 6 months
- Weekly alcoholic intake >14 drinks (168 oz beer, 56 oz wine, 14 oz hard liquor)
- Drugs known to influence fecal microbiota: Regular use of fiber supplements such as Metamucil, probiotics, prebiotics, laxatives, stool softeners, H2 blockers, proton pump inhibitors (PPI) or antacids.
- Antibiotic use within 3 months prior to or during study participation
- Colonoscopy or colonoscopy prep within 3 months prior to or during study
- Infrequent (<3/wk) or excessive (>3/d) number of regular bowel movements
- History of a bilateral mastectomy with nodal dissection
- Consume ≥3 servings of fruits and vegetables daily one average
- Gastrointestinal diseases, conditions, or medications influencing gastrointestinal absorption including active peptic ulcer disease or inflammatory bowel disease which will be found based on the self-report during the screening visit
- Diabetes and/or use of diabetes medications
- Unstable thyroid disease or adjustment of thyroid medication in past 6 months
- Abnormal values of standard blood biochemistries that interfere with study outcomes based on study physician's discretion
- Infection or immunization within 30 days prior to study admission
- Use anticoagulants, such as heparin, warfarin (coumadin), or Plavix in past 6 months
- On or planning to be on a weight loss regimen
- Gain or loss of ≥5% body weight in the last 6 months
- Inability to refrain from ASA/NSAID/Tylenol use x 720 prior to study blood draws
- Regular use of any dietary supplements containing vitamins, minerals, herbal or other plant-based preparations, fish oil supplements (including cod liver oil) prebiotics, probiotics or homeopathic remedies; however, subjects who are willing to refrain from the use of these supplements 30 days prior to enrollment and throughout the entire study may be considered eligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: fruit/vegetable supplement (FVS)
The experimental product will be prepared by combing Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend in an equal proportion.
|
The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
|
|
PLACEBO_COMPARATOR: placebo
The placebo comprises microcrystalline cellulose and 0.5% magnesium stearate.
|
The product does not contain nutrients present in the FVS.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mitochondrial function
Time Frame: at end of 6-week intervention
|
Targeted central carbon metabolomic in peripheral blood mononuclear cells
|
at end of 6-week intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
metabolomics
Time Frame: at end of 6-week intervention
|
non-targeting plasma metabolomics
|
at end of 6-week intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
phytochemical concentrations in plasma
Time Frame: at end of 6-week intervention
|
Concentrations of plasma phenolics, carotenoids, and tocopherols
|
at end of 6-week intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2920
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitochondrial Functions
-
Universidad Nacional de Educación a DistanciaMinistry of Economy and Competitiveness (MINECO) - Government of SpainUnknownMemory Functions | Executive FunctionsSpain
-
Yuzuncu Yıl UniversityCompletedAnesthesia | Geriatric | Liver Functions | Kidney FunctionsTurkey
-
Mansoura UniversityNot yet recruitingCognitive Functions
-
Prof. Dominique de Quervain, MDClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMemory FunctionsSwitzerland
-
Maharishi Markendeswar University (Deemed to be...RecruitingCognitive FunctionsIndia
-
Eastern Mediterranean UniversityCompletedGastrointestinal FunctionsCyprus
-
Prof. Dominique de Quervain, MDClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMemory FunctionsSwitzerland
-
Shenzhen UniversityNot yet recruitingExecutive Functions (EF)
-
Foundation University IslamabadCompletedBalance | Cognitive FunctionsPakistan
-
NovaSightNot yet recruiting
Clinical Trials on fruit/vegetable supplement (FVS)
-
Wholesome WaveYale-Griffin Prevention Research Center; One Community HealthCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus | PovertyUnited States
-
University of California, Los AngelesCompletedIntestinal Bacteria Flora DisturbanceUnited States
-
St. Catherine UniversityUniversity of MinnesotaCompletedCardiovascular DiseasesUnited States
-
Albert Einstein Healthcare NetworkRobert Wood Johnson FoundationCompletedFocus of the Study is on the Use of Incentives to Promote | Healthier Eating in Low-income CommunitiesUnited States
-
Birmingham Community Healthcare NHSNSA, LLCCompleted
-
Oregon Health and Science UniversityCompletedHyperlipidemiasUnited States
-
The University of Tennessee, KnoxvilleWithdrawn
-
Academia Sinica, TaiwanNational Taiwan University HospitalCompleted
-
Arizona State UniversityKaren L. Sweazea; Brendan MillerCompletedHigh Blood Pressure | Flow Mediated DilationUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHead and Neck CancerUnited States